Author:
Olivier Timothée,Prasad Vinay
Reference12 articles.
1. The role of censoring on progression free survival: oncologist discretion advised;Prasad;Eur J Cancer,2015
2. Censored patients in Kaplan–Meier plots of cancer drugs: an empirical analysis of data sharing;Rosen;Eur J Cancer,2020
3. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials;Olivier;J Clin Epidemiol,2021
4. Informative censoring - a neglected cause of bias in oncology trials;Templeton;Nat Rev Clin Oncol,2020
5. Agarwal N., et al. CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 〈https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.18〉.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献